Australia markets open in 2 hours 18 minutes

Zhejiang Shouxiangu Pharmaceutical Co., Ltd. (603896.SS)

Shanghai - Shanghai Delayed price. Currency in CNY
Add to watchlist
20.01+0.11 (+0.55%)
At close: 03:00PM CST
Currency in CNY

Valuation measures4

Market cap (intra-day) 3.95B
Enterprise value 3.21B
Trailing P/E 14.74
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)5.11
Price/book (mrq)1.79
Enterprise value/revenue 4.20
Enterprise value/EBITDA 9.12

Trading information

Stock price history

Beta (5Y monthly) 0.34
52-week change 3-51.40%
S&P500 52-week change 320.52%
52-week high 344.00
52-week low 319.76
50-day moving average 322.16
200-day moving average 327.04

Share statistics

Avg vol (3-month) 31.91M
Avg vol (10-day) 31.73M
Shares outstanding 5198.24M
Implied shares outstanding 6198.24M
Float 8112.91M
% held by insiders 144.02%
% held by institutions 19.50%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 40.39
Forward annual dividend yield 41.85%
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 40.98
Payout ratio 432.12%
Dividend date 3N/A
Ex-dividend date 420 June 2024
Last split factor 21.3:1
Last split date 326 May 2022

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 33.66%
Operating margin (ttm)27.29%

Management effectiveness

Return on assets (ttm)4.15%
Return on equity (ttm)12.71%

Income statement

Revenue (ttm)799.09M
Revenue per share (ttm)4.07
Quarterly revenue growth (yoy)7.20%
Gross profit (ttm)N/A
EBITDA 275.88M
Net income avi to common (ttm)269M
Diluted EPS (ttm)1.35
Quarterly earnings growth (yoy)23.20%

Balance sheet

Total cash (mrq)1.62B
Total cash per share (mrq)8.18
Total debt (mrq)772.02M
Total debt/equity (mrq)34.17%
Current ratio (mrq)3.64
Book value per share (mrq)10.95

Cash flow statement

Operating cash flow (ttm)285.53M
Levered free cash flow (ttm)-408.5M